舒尼替尼联合吉西他滨治疗晚期非小细胞肺癌合并肾转移患者的Cr、BUN、PRO水平影响  

Effects of sunitinib combined with gemcitabine on the levels of Cr,BUN and PRO in patients with advanced non-small cell lung cancer complicated with renal metastasis

作　　者：包志伟 鲁雪莲 程新芹 Bao Zhi-wei;Lu Xue-lian;Cheng Xin-qin(Jianghan University,Hospital,Wuhan City,Hubei Province,Internal Medicine,Wuhan 430000,China;Hubei integrated traditional Chinese and Western Medicine Hospital,Internal medicine,Wuhan 430000,China)

机构地区：[1]湖北省武汉市江汉大学医院内科,武汉430000 [2]湖北省中西医结合医院内科,武汉430000

出　　处：《湖南师范大学学报（医学版）》2021年第2期153-156,共4页Journal of Hunan Normal University(Medical Sciences)

摘　　要：目的:讨论舒尼替尼联合吉西他滨治疗晚期非小细胞肺癌合并肾转移患者的Cr、BUN、PRO水平影响。方法:本次研究选取湖北省武汉市江汉大学医院2013年1月1日~2016年12月31日接收治疗的晚期非小细胞肺癌合并肾转移患者96例,采用随机数表法将入选患者分为两组,每组48例,对照组患者给予常规治疗联合吉西他滨治疗,观察组患者在对照组的基础上给予舒尼替尼联合治疗,观察比较两组患者治疗后临床疗效和毒副作用发生率,比较两组患者治疗前、后肾功能血肌酐(Scr)、尿素氮(BUN)指标以及血清血清神经元特异性烯醇化酶(NSE)和胃泌素释放肽前体(ProGRP)指标变化情况。结果:观察组患者治疗后ORR为60.42%,对照组患者ORR为27.08%,观察组明显高于对照组,差异有统计学意义,两组患者治疗前Scr、BUN指标比较无差异,治疗后,两组患者Scr、BUN指标均有升高,但观察组Scr(124.72±14.65)mol/L、BUN(7.29±1.97)mmol/L明显低于对照组Scr(131.58±15.67)mol/L、BUN(8.34±2.15)mmol/L,两组比较差异有统计学意义,两组患者治疗前NSE、Pro-GRP指标比较无差异,治疗后,观察组NSE(20.15±5.24)mol/L、ProGRP(56.73±8.49)ng·L^(-1)明显低于对照组NSE(22.74±6.17)mol/L、ProGRP(61.52±7.15)ng·L^(-1),两组比较差异显著,观察组治疗后肝功能异常、血小板计数下降、白细胞计数下降、恶心呕吐以及乏力等毒副作用发生率均明显低于对照组,差异有统计学意义。结论:给予晚期非小细胞肺癌合并肾转移患者舒尼替尼联合吉西他滨治疗临床疗效显著,可改善患者血清指标,减少毒副作用的发生,值得临床推广应用。Objective To investigate the effect of sunitinib combined with gemcitabine on the levels of Cr,BUN and PRO in patients with advanced non-small cell lung cancer complicated with renal metastasis.Methods A total of 96 patients with advanced non-small cell lung cancer with renal metastasis were enrolled in Jianghan University Hospital in Wuhan,Hubei Province from January 1,2013 to December 31,2016,all the patients were divided into two groups of 80 cases randomly,patients in the control group received routine treatment with gemcitabine,and the patients in the observation group were given sunitinib combination therapy on the basis of the control group,to observe the clinical efficacy and side effects of the two groups after treatment,the levels of serum creatinine (Scr),urea nitrogen (BUN) and serum serum neuron specific enolase (NSE) and gastrin release peptide (ProGRP) were measured before and after treatment.Results ORR was 60.42% in the observation group and 27.08% in the control group,the observation group was significantly higher than the control group,the difference was statistically significant,there were no significant differences in Scr and BUN between the two groups.After treatment,Scr and BUN were increased in the two groups,but Scr (124.72±14.65)mol/L,BUN (7.29±1.97) mmol/L was significantly lower than Scr (131.58±15.67)mol/L,BUN (8.34±2.15) mmol/L,the difference between the two groups was statistically significant,there was no significant difference in NSE and Pro-GRP between the two groups,after treatment,the levels of NSE (20.15±5.24)mol/L and ProGRP (56.73±8.49) ng·L^(-1) in the observation group were significantly lower than those in the control group (22.74±6.17)mol/L,ProGRP (61.52±7.15) ng·L^(-1),the difference between the two groups was significant,the incidence of side effects such as decreased liver function,decreased platelet count,decreased white blood cell count,nausea and vomiting,and fatigue were significantly lower in the observation group than in the control group.Conclusion Fo

关 键 词：舒尼替尼 吉西他滨 非小细胞肺癌 肾转移 毒副作用 

分 类 号：R563[医药卫生—呼吸系统]